Legislation aims to ensure ‘fair and accurate’ Alzheimer’s treatment coverage decisions
By
Kimberly Bonvissuto
Nov 21, 2023
Federal legislation that would prevent the federal government from imposing wide-reaching coverage restrictions on Alzheimer’s treatments was reintroduced last week, providing “fair and accurate”...
CMS announces Alzheimer’s drug coverage policy, but ‘the devil is in the details,’ experts say
By
Kimberly Bonvissuto
Jun 01, 2023
A Thursday announcement by the Centers for Medicare & Medicaid Services regarding coverage of Alzheimer’s drugs is being met with skepticism by some industry advocates who say that “the devil is in...
Inconsistent state regulations, staff training produce wide variations among states’ antipsychotic...
By
Kimberly Bonvissuto
Feb 28, 2023
Researchers are calling for a closer look at the use of antipsychotics among assisted living residents with dementia after a study found wide variations in prescribing patterns.
Feds’ antipsychotic drug reduction efforts in assisted living fail to produce success seen in nursing...
By
Alicia Lasek
Aug 23, 2022
A federal initiative to reduce antipsychotic prescribing in long-term care facilities failed to impact prescriptions in assisted living residents with dementia, the first study of its kind has found.
Antipsychotic prescribing increases in assisted living during pandemic: study
By
Kimberly Bonvissuto
Apr 11, 2022
The prescribing of antipsychotic medications in assisted living communities and nursing homes has increased by 1.5% since the beginning of the COVID-19 pandemic, according to a recent study.
Stable use of antipsychotics in assisted living during pandemic ‘reassuring’: study
By
Kimberly Bonvissuto
Mar 04, 2022
Researchers comparing recent prescribing trends of psychotropic and pain medications in assisted living communities and nursing homes said they were reassured by relatively stable patterns despite pandemic...